Phaseline

Targets › HLA-G

HLA-G (HLA class I histocompatibility antigen, alpha chain G): drug programs, companies and trials

5 programs from 4 companies in 5 trials: 5 Phase 1; Oncology, Other; next expected readout Dec 2026.

[Isoform 1]: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. (UniProt, P17693)

Open in Phaseline: the race on HLA-G, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shine-On BiomedicalSOB100
HLA-G targeted exosome with anti-HLA-G VHH nanobody
HLA-GPhase 1Healthy SubjectsDec 2026
Tizona TherapeuticsTTX-080
HLA-G antagonist
HLA-GPhase 1CancerJun 2027
Ever Supreme Bio TechnologyHLA-G-CAR.BiTE allogeneic γδ T cells
HLA-G-targeted CAR (chimeric antigen receptor) BiTE (bispecific T cell engager) allogeneic
HLA-GPhase 1Solid TumorJun 2027
Shine-On BiomedicalSOA101
Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3
CD274, HLA-G, CD3EPhase 1Solid TumorsFeb 2028
Cancer Research UKUCB4594
anti-HLA-G monoclonal antibody
HLA-GPhase 1Advanced Solid TumoursNov 2029

Conditions

Solid Tumors (1) Healthy Subjects (1) Advanced Solid Tumours (1) Cancer (1) Solid Tumor (1)

Modalities

small molecule (3), mixed (1), other (1)

Companies

Shine-On Biomedical (2) Cancer Research UK (1) Tizona Therapeutics (1) Ever Supreme Bio Technology (1)

Related targets

CD274 (1) CD3E (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.